Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ABEO vs CISS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABEO Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

ABEO Overall Winner 6-Pillar Tally: ABEO 3 – 3 CISS Matrix Metrics: ABEO 6 – 4 CISS

As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over C3is Inc. (CISS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ABEO carries a Unified Composite Score of 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin), whereas CISS carries 33.6/100 (SELL) at $1.23 (N/M Forward P/E, 24.6% operating margin).

  • Technical & Structure Timing Caution: ABEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6); meanwhile CISS is in a Breakdown options structure phase (RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABEO vs CISS
ABEO NASDAQ Head-to-Head Winner
Abeona Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.42
-1.22% 1D
Market Cap $167.4M
TTM Revenue $39M
Forward P/E 18.7x
Beta / 30D Vol 0.60β · 149% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 60.0 Fund 61.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.9%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $3.39 · SMA50: $4.38
CISS NASDAQ
C3is Inc. Common Stock
Deep Sea Foreign Transportation Of Freight
$1.23
+4.24% 1D
Market Cap $991,199
TTM Revenue $36.2B
Forward P/E N/M
Beta / 30D Vol 11.91β · 1054% Vol
Unified Composite Score
33.6 / 100 SELL
Tech 5.0 Fund 29.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $1.05 · SMA50: $0.95

6-Pillar Scorecard Institutional Category Breakdown (ABEO 3 – 3 CISS)

Columns: Metric · ABEO · CISS
1. Valuation Multiples ABEO
Forward P/E 18.7x N/M
Trailing P/E 18.7x N/M
PEG Ratio N/M N/M
EV / Revenue 3.0x N/M
2. Growth & Scale ABEO
Revenue Growth (YoY) +2745.0% +249.0%
Earnings Growth (YoY) +0.0% +193.3%
TTM Revenue (USD) $39M $36.2B
Market Cap $167.4M $991,199
3. Profitability & Quality CISS
Gross Margin -3.5% 68.1%
Operating Margin -186.1% 24.6%
Net Profit Margin -160.3% 27.4%
Return on Equity (ROE) -42.1% 17.1%
4. Balance Sheet & Cash Flow CISS
Cash Generation (TTM) -$66M $13.4B EBITDA
Cash Flow Margin N/A 36.9% EBITDA Mgn
Net Cash / Leverage $50M Net Cash $384.31 Book/Sh · 17.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABEO
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 165.8% (27th %ile) N/A (N/A)
Put/Call OI Skew 0.26x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CISS
OpEx & R&D Intensity N/A 43.5% of Rev ($15.8B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Marine Shipping Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABEO (6) vs CISS (4)
Institutional Metric ABEO CISS Criterion Row Edge
Market Capitalization
Scale
$167.4M $991,199 Larger Scale ABEO
Trailing P/E Ratio
Valuation
18.7x N/M Lower Multiple ABEO
Forward P/E Ratio
Valuation
18.7x N/M Lower Multiple ABEO
Revenue Growth (YoY)
Growth
+2745.0% +249.0% Higher Growth ABEO
Operating Margin (TTM)
Profitability
-186.1% 24.6% Higher Margin CISS
Net Profit Margin
Profitability
-160.3% 27.4% Higher Margin CISS
Return on Equity (ROE)
Capital Efficiency
-42.1% 17.1% Higher ROE CISS
52-Week Range Position
Momentum
6% ($2–$8) 20% ($0–$6) Stronger Trend CISS
Beta / 30D Volatility
Risk Regime
0.60β · 149% Vol 11.91β · 1054% Vol Lower Realized Risk ABEO
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 33.6 / 100 (SELL) Higher Composite ABEO
Trailing 12M Revenue (USD)
Operating Scale
$39M $36.2B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-3.5% 68.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M ($50M Net Cash) $13.4B EBITDA ($384.31 Book/Sh · 17.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CISS +181.09 pp
ABEO: -45.86% · CISS: +135.23%
3M Horizon CISS +7.2 pp
ABEO: -60.07% · CISS: -52.87%
6M Horizon CISS +7.63 pp
ABEO: -55.51% · CISS: -47.88%
1Y Horizon CISS +16.93 pp
ABEO: -42.38% · CISS: -25.45%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ABEO Revenue CISS Revenue ABEO Op. Margin CISS Op. Margin Margin Leader
FY2017 $0M N/A -3325.7% N/A ABEO
FY2018 $0M N/A -1940.2% N/A ABEO
FY2020 $10M N/A -814.2% N/A ABEO
FY2021 $0M N/A -2994.5% N/A ABEO
FY2022 $0M N/A -3600.8% N/A ABEO
FY2023 $0M $30M -1346.7% 36.3% CISS
FY2024 N/A $40M N/A 23.8% CISS
FY2025 $10M $30M -1536.9% 3.9% CISS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABEO BREAKDOWN
71d in phase · OBV NEUTRAL
Current IV 165.8%
IV Percentile 27th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CISS BREAKDOWN
64d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CISS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABEO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $167.4M market capitalization and -186.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CISS Moat Profile Scale & Operating Efficiency Moat
Marine Shipping Operator
Competes within the Marine Shipping value chain with $991,199 market capitalization and 24.6% operating margin.
OpEx & R&D Reinvestment 43.5% of Rev ($15.8B)
90D Engineering Disclosures 0 Published

Investor FAQ ABEO vs CISS Key Questions & Quantitative Answers

As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over C3is Inc. (CISS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ABEO carries a Unified Composite Score of 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin), whereas CISS carries 33.6/100 (SELL) at $1.23 (N/M Forward P/E, 24.6% operating margin). Technical & Structure Timing Caution: ABEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6); meanwhile CISS is in a Breakdown options structure phase (RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABEO leads the Growth & Scale pillar: ABEO posts +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin), compared with CISS at +249.0% YoY revenue growth and +193.3% YoY earnings growth on $36.2B TTM revenue (68.1% gross margin, 24.6% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), ABEO cumulative revenue shifted +0.0% while CISS shifted +0.0%. In operating R&D and SG&A reinvestment, ABEO deploys N/A (0 90-day corporate R&D disclosures) versus 43.5% of Rev ($15.8B) (0 disclosures) for CISS.

ABEO screens cheaper on headline valuation multiples. ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 3.0x EV/Revenue (unreported FCF margin), whereas CISS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (36.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABEO (-42.1% ROE) versus CISS (17.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk). By comparison, CISS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (11.91β · 1054% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.